WorldCare Clinical, LLC (WCC) introduced a new service offering that supports expert readers in a timely and transparent manner to complete cardiovascular endpoint committee reviews quickly and cost-effectively.
In response to FDA guidance and growing requests from other regulatory agencies that place new emphasis on assessing and minimizing cardiovascular risk, WCC has developed a comprehensive and easy-to-use solution for cost-effective, Blinded Independent Central Review (BICR) of adverse events (AEs) using the Medical Dictionary for Regulatory Activities (MedDRA) and other safety coding dictionaries. WCC’s new service offering builds upon the company’s extensive Endpoint Assessment Committee (EAC) services and employs its WorldPRO® image management platform to capture, quantify and consolidate virtually any type of clinical data for interpretation by sub-specialty trained experts.
"We’re excited to introduce the first of several new services we’ll be offering to sponsors in the coming months," said Richard Walovitch, PhD, president of WorldCare Clinical, LLC. "Through our long-standing strategic relationship with Massachusetts General Hospital (MGH), we’re able to deliver the most accurate assessments by providing access to leading clinical experts to meet each trial’s specific protocol requirements. This combined with our proprietary digital portal, WorldPRO, provides the ability to streamline the BICR process and highlights the flexibility of our capabilities."
WCC’s new service offering for cardiovascular endpoint committees consists of the following:
The WorldPRO system can be accessed by multiple clinical scientists at different locations to collate potential Events of Interest (EoIs) for internal or external review. Equipped with a smart work queue and automated adjudication workflow, WorldPRO allows clinicians to review data efficiently to further expedite the review process. Additionally, WCC has included a standardized scoring system to assess the degree of certainty of the EoI. This unique feature enables WCC to better determine variance in AE coding between independent reviews, while maintaining training and testing programs that maximize the precision and accuracy of a clinical trial.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.